T. Rowe Price Associates’s Anika Therapeutics ANIK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-8,998
| Closed | -$215K | – | 2933 |
|
|
2022
Q3 | $215K | Buy |
+8,998
| New | +$215K | ﹤0.01% | 2514 |
|
|
2022
Q1 | – | Sell |
-7,659
| Closed | -$274K | – | 2968 |
|
|
2021
Q4 | $274K | Buy |
7,659
+435
| +6% | +$15.6K | ﹤0.01% | 2626 |
|
|
2021
Q3 | $307K | Buy |
7,224
+27
| +0.4% | +$1.15K | ﹤0.01% | 2563 |
|
|
2021
Q2 | $312K | Buy |
7,197
+708
| +11% | +$30.7K | ﹤0.01% | 2577 |
|
|
2021
Q1 | $265K | Sell |
6,489
-17
| -0.3% | -$694 | ﹤0.01% | 2596 |
|
|
2020
Q4 | $294K | Sell |
6,506
-100
| -2% | -$4.52K | ﹤0.01% | 2426 |
|
|
2020
Q3 | $234K | Hold |
6,606
| – | – | ﹤0.01% | 2373 |
|
|
2020
Q2 | $249K | Buy |
+6,606
| New | +$249K | ﹤0.01% | 2298 |
|
|
2020
Q1 | – | Sell |
-6,445
| Closed | -$334K | – | 2511 |
|
|
2019
Q4 | $334K | Buy |
6,445
+522
| +9% | +$27.1K | ﹤0.01% | 2280 |
|
|
2019
Q3 | $325K | Sell |
5,923
-4,630
| -44% | -$254K | ﹤0.01% | 2249 |
|
|
2019
Q2 | $429K | Buy |
10,553
+20
| +0.2% | +$813 | ﹤0.01% | 2164 |
|
|
2019
Q1 | $319K | Buy |
10,533
+40
| +0.4% | +$1.21K | ﹤0.01% | 2267 |
|
|
2018
Q4 | $353K | Buy |
10,493
+23
| +0.2% | +$774 | ﹤0.01% | 2212 |
|
|
2018
Q3 | $442K | Buy |
10,470
+86
| +0.8% | +$3.63K | ﹤0.01% | 2191 |
|
|
2018
Q2 | $332K | Buy |
+10,384
| New | +$332K | ﹤0.01% | 2305 |
|
|
2016
Q3 | – | Sell |
-5,440
| Closed | -$292K | – | 2527 |
|
|
2016
Q2 | $292K | Hold |
5,440
| – | – | ﹤0.01% | 2187 |
|
|
2016
Q1 | $243K | Hold |
5,440
| – | – | ﹤0.01% | 2234 |
|
|
2015
Q4 | $208K | Buy |
+5,440
| New | +$208K | ﹤0.01% | 2293 |
|